Pioneering Targeted Delivery of Genetic Medicines
Code Bio is developing transformational, non-viral, genetic medicines to treat and potentially cure serious and life-threatening diseases
Code Bio leverages its proprietary, novel, multivalent, synthetic DNA delivery platform, 3DNA®, which has been engineered to overcome many of the challenges inherent with delivery of genetic medicines, such as: dose related toxicity, off target effects, immunogenicity, gene size and delivery limitations, bioavailability, ability to re-dose, and vector manufacturing complexity.
The Company is advancing an internal pipeline of genetic medicines focused on select diseases without a cure (Duchenne’s Muscular Dystrophy and Type 1 Diabetes), as well as establishing partnerships to take forward programs in both rare and prevalent diseases.
Our 3DNA platform is engineered to overcome serious limitations of delivering genetic medicines by improving tissue specific targeting and bioavailability, as well as offering modularity to deliver multiple modalities while minimizing off-target effects.
We are advancing an internal pipeline of genetic medicines to treat rare and prevalent diseases, with initial programs focused on treating Duchenne Muscular Dystrophy (DMD) and Type 1 Diabetes (T1D).
Partner with Us
We are actively engaged in establishing partnerships to take forward strategic programs that hold promise for rare and prevalent diseases.